Concerning severe-to-critical COVID-19 patients at baseline, retrospective studies on TCZ efficacy showed improved outcomes at various time-points after admission [17, 35–42], being associated to critical disease only in one study [41] or to CRP>15 mg/dl at baseline only [39, 42]. This evidence concerns the gene CRP and COVID-19.